RJA
MREO

Raymond James & Associates’s Mereo BioPharma MREO Stock Holding History

Raymond James & Associates’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,089
Closed -$51K – 4159
2021
Q1 		$51K Buy
+15,089
New +$53.3K ﹤0.01% 3853

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Raymond James & Associates's MREO Position: Q2 2021 in Review

Raymond James & Associates sold out of Mereo BioPharma (MREO) in Q2 2021, closing a stake of 15,089 shares — an estimated $51K sold.

Raymond James & Associates first reported a position in MREO in Q1 2021 and held it in 1 quarter. The position peaked at $51K in Q1 2021. 71 funds tracked by Wall St. Rank hold MREO as of Q2 2021.

  • Raymond James & Associates reported no remaining Mereo BioPharma position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 15,089 Mereo BioPharma shares in Q2 2021, an estimated $51K.
  • Raymond James & Associates first reported a position in Mereo BioPharma in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's Mereo BioPharma position peaked at $51K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.